

CHEST 2025 Faculty/Planner Disclosures

NAME	DISCLOSURES
Adams, Sandra (MS, MD, FCCP)	Educational Grant for CME relationship with AstraZeneca; 05/2023 - 12/2025
Addrizzo-Harris, Doreen (MD, FCCP)	PI clinical trial relationship with Verona; 2024 to present; member DMSB relationship with Mannkind; 5/2024 to present; PI clinical trial relationship with Armata; 4/2024; PI for a clinical trial; relationship with AN2; 2021 to 2024; PI of research trial relationship with Boehringer; 2022-2025; PI for research grant relationship with Zambone; 2018-2021; PI for research trial relationship with Hill-Rom; 2019-2025; Clinical Trial, I am PI relationship with Insmed; 2017-2025; clinical trial relationship with Astra zeneca; 8/2025; Advisory Committee Member relationship with boehringer ingelheim; 7/2025 to present; Advisory Committee Member relationship with sanofi; 2025 to present
Adegunsoye, Ayodeji (MD, PhD, FCCP)	Advisory Committee Member relationship with Genentech; 2019-2022; Consultant relationship with Avalyn Pharma; 2024-2025; Advisory Committee Member relationship with Inogen; 2022-2025; Consultant relationship with Abbvie; 2025; Speaker/Speaker's Bureau relationship with Boehringer Ingelheim; 2018-2025; Advisory Committee Member relationship with Boehringer Ingelheim; 2018-2025
Akkanti, Bindu (MD, FCCP)	Research Grant relationship with Alung; \$1001 - \$5000; Speaker/Speaker's Bureau relationship with Jansen; 2021-2023; Speaker/Speaker's Bureau relationship with Abiomed; 2022; Speaker/Speaker's Bureau relationship with Abiomed; 2022-present; Speaker/Speaker's Bureau relationship with Abiomed; 2023; Speaker/Speaker's Bureau relationship with Janssen; 2023; Scientific Medical Advisor relationship with Alung/Livanova; 2023

Akuthota, Praveen (MD)	Site PI for trials in EGPA and Hypereosinophilic Syndrome relationship with AstraZeneca; 2020-2022; Site PI for Hypereosinophilic Syndrome trial relationship with GlaxoSmithKline; 2018-2020; Consultant relationship with AstraZeneca; 2017 - present; Consultant relationship with Enveda Biosciences; 2025-present; Consultant relationship with GlaxoSmithKline; 2017-present; CME speaker relationship with AKH, Inc; 2019-present; CME speaker relationship with Projects In Knowledge; 2019-present; CME speaker relationship with PRIME Healthcare; 2019-2021; Clinical Trial Site PI relationship with Regeneron; February 2021-; Consultant relationship with Sanofi; 2021-present; Scientific Medical Advisor relationship with Sanofi; 1/1/2022-present; Site PI relationship with Regeneron; 2021-present; Site PI; Scientific Advisor relationship with AstraZeneca; 2018-present; Scientific Medical Advisor relationship with GlaxoSmithKline; 2020-present; Consultant relationship with Connect Biopharma; 2024-present; Consultant relationship with Amgen; 2024; Consulting; Advisory Boards; Research Funding relationship with AstraZeneca; 2017 - present; research funding; advisory boards relationship with GlaxoSmithKline; 2017-present; Faculty for sponsored course relationship with AstraZeneca; 2018 - 2020
Alraiyes, Abdul Hamid (MD, FCCP)	Consultant relationship with Intuitive; 2/26/2025; Consultant relationship with Intuitive; 1 year
Apicella, Michelle (PA)	advisory board participant relationship with Insmed; 1/2024-10/2024
Argento, Angela (MD, FCCP)	Consultant relationship with PulmonX; 2019-2022; Consultant relationship with AstraZeneca; 2024-present; Consultant relationship with BD; 2024-present; Education course faculty relationship with Olympus; 2022-present; Consultant relationship with Boston Scientific; 2021- 2023; Consultant relationship with Biodesix; 2018-2023; Consultant relationship with cook medical; 2019-present; Consultant relationship with Intuitive; 2019-2022
Assaad, Murad	Speaker/Speaker's Bureau relationship with Axsome Therapeutics, Inc.; 2024; Speaker/Speaker's Bureau relationship with Avadel Pharmaceuticals; 2024; Advisory Committee Member relationship with Jazz Pharmaceuticals; 2024

Assassi, Shervin	Advisory Committee Member relationship with Abbvie; ongoing; Consultant relationship with TeneoFour; Ongoing; Medical Advisor relationship with PeerView Institute for Medical Education CME; Ongoing; Advisory Committee Member relationship with Boehringer Ingelheim; Ongoing; Principal Investigator relationship with aTyr; ongoing; Consultant relationship with Abbvie; Ongoing; Consultant relationship with Takeda; Completed; Consultant relationship with Mitsubishi Tanabe; Ongoing; Consultant relationship with CSL Behring; Ongoing; Consultant relationship with AstraZeneca; Ongoing; Principal investigator relationship with Janssen; ongoing; Speaker relationship with Boehringer Ingelheim; Ongoing
Assayag, Deborah (MD)	Advisory Committee Member relationship with Avalyn; 2024; Advisory Committee Member relationship with Boehringer-Ingelheim; 2020-2025; Research Grants relationship with Boehringer-Ingelheim; 2020-2024
Bade, Brett (MD)	Co-investigator on industry trial relationship with Nucleic Ltd; 2023-present; Co-investigator on industry trial relationship with Delfi; 2022-present; Co-investigator on industry trial relationship with Biodesix; 9/2022-present
Baig, Saqib (MD)	Consultant relationship with Rhythmic health; 2023; Consultant relationship with Verona; March 2023; Consultant relationship with Regeneron; Nov 2022; Content reviewer relationship with Ubie Pte; June 2022 - Dec 2022; Independent consultant relationship with GLG; Oct 2024-ongoing
Balkissoon, Ronald (MSc, MD)	Speaker/Speaker's Bureau relationship with Glaxo Smith Kline; 2/23-2/25; Advisory Board relationship with Glaxo Smith Kline; 1/2022 to 10/2024; Speaker/Speaker's Bureau relationship with Astra Zeneca; 1/22- 10/2024; Speaker/Speaker's Bureau relationship with Sanofi; 1/2022-10/2024; Speaker/Speaker's Bureau relationship with Regeneron; 1/23 -present

Bansal, Sandeep (MBBS, FCCP)	Consultant relationship with Veracyte; 2019 - Present; Speaker/Speaker's Bureau relationship with Sanofi; 2020 - present; Speaker/Speaker's Bureau relationship with Regeneron; 2020 - present; Speaker/Speaker's Bureau relationship with Boehringer Ingelheim; 2019 - present; Speaker/Speaker's Bureau relationship with GlaxoSmithKline; 2019 - present; Speaker/Speaker's Bureau relationship with Takeda Pharmaceutical Company; 2022 - present; Shareholder - Public relationship with Veracyte; 11/2019 - 03/2024; Consultant relationship with Circulogene; 2019 - Present; Speaker/Speaker's Bureau relationship with Mylan Speciality and Theravance Biopharma US; 2023 - present; Equity owner relationship with Circulogene; 10/2020-present; Consultant relationship with Biodesix; 2019-present; Speaker/Speaker's Bureau relationship with Amgen; 2022 - present; Speaker/Speaker's Bureau relationship with AstraZeneca; 2022 - present; Consultant relationship with Noah Medical Corporation; 2024 - present
Barta, Julie (MD)	Advisory Committee Member relationship with Freenome; 2022; Advisory Committee Member relationship with Guardant Health; 2022; Scientific Medical Advisor relationship with Delfi Diagnostics, Inc; 3/31/22 to 3/30/24; Research grant relationship with Genentech; 2019-2022; Research grant relationship with Prevent Cancer Foundation; 2021-2024
Bartolome, Sonja (MD, FCCP)	Consultant relationship with Janssen; Limited event; Consultant relationship with Liquidia; Limited event; Consultant relationship with Merck; Single event
Basavaraj, Ashwin (MD, FCCP)	Principal investigator in clinical trial relationship with Baxter; 2020- March 2023; Consultant relationship with Insmed; 2018- March 2023
Bauer Ventura, Iazsmin (MD)	Advisory Committee Member relationship with Boehringer Ingelheim; October 2024
Bawaadam, Hasnain (MD, FCCP)	Speaker/Speaker's Bureau relationship with Intuitive Surgical; 01/01/2022 - present; Consultant relationship with Siemens; 01/01/2023 - present; Consultant relationship with CIRCULOGENE; 01/01/2024 - present; Consultant relationship with BIODESIX; 01/01/2024 - present; Consultant relationship with COOK Medical; 01/01/2024 - present
Beattie, Jason (MD)	Speaker/Speaker's Bureau relationship with Intuitive Surgical; 05/2023 to present; Consultant relationship with Impact Biotech; 06/2023-08/2023
Begnaud, Abbie (BS, MD, FCCP)	DSMB relationship with Biodesix; 2021 - 2024 (ongoing)
Bender, William (BA, MPH, MD)	Advisory Committee Member relationship with Baxter; 11/13/2024
Bernardo, Roberto (MD, MS)	Advisory Committee Member relationship with United Therapeutics; 05/2023; Consultant relationship with Merck; 11/2024; Consultant relationship with Janssen Pharmaceuticals; 10/2024

Betancourt, Jaime (MD, FCCP)	Speaker/Speaker's Bureau relationship with Vapotherm, Inc; 2019-Present; Speaker/Speaker's Bureau relationship with Boehringer-Ingelheim Pharmaceutical; 2014-Present
Bhattacharjee, Rakesh	Consultant relationship with Jazz Pharmaceuticals; 2022-current; Speaker's Bureau relationship with Harmony Bioscience; 2024-current; Consultant relationship with Avadel Pharmaceuticals; 2023-current
Blubaugh, Richard	Owner/Founder relationship with Safer Medical Products, LLC; 8/2020 - 11/2024
Boente, Ryan (MD)	Consultant relationship with Boehringer Ingelheim; April - October 2024
Bon, Jessica	Advisory Committee Member relationship with Sanofi; 4/27/24; Speaker/Speaker's Bureau relationship with GSK; 2024; Advisory Committee Member relationship with Regeneron; 5/8/24; Advisory Committee Member relationship with Verona Pharma; 4/13/24; Consultant relationship with Chiesi USA; 1/1/24 - 6/30/25; Speaker/Speaker's Bureau relationship with Sanofi; 2024; Advisory Committee Member relationship with GSK; 2024; Advisory Committee Member relationship with Regeneron; 2024; Consultant relationship with Chiesi; 2024; Advisory Committee Member relationship with Sanofi; 2024; Advisory Committee Member relationship with Verona Pharma; 2024
Boncyk, Christina	Consultant relationship with Sedana Medical; 2021-Present
Bork, Stephanie (APRN-BC)	Advisory Board Consultant relationship with Regeneron; 4/2025-10/2025; Advisory Board Consultant relationship with Sanofi; 6/2025
Bourbeau, Jean (MD, MSc, FCCP)	Speaker/Speaker's Bureau relationship with Sanofi; 24 months; Speaker/Speaker's Bureau relationship with GlaxoSmithKline?Canada Ltd; 24 months; Speaker/Speaker's Bureau relationship with Trudell Canada Ltd; 24 months; Speaker/Speaker's Bureau relationship with Trudell Canada Ltd; 24 months; Speaker/Speaker's Bureau relationship with Novartis; 24 months; Speaker/Speaker's Bureau relationship with GlaxoSmithKline?Canada Ltd; 24 months; Speaker/Speaker's Bureau relationship with Boehringer Ingelheim Canada Ltd; 24 months; Speaker/Speaker's Bureau relationship with Boehringer Ingelheim Canada Ltd; 24 months; Speaker/Speaker's Bureau relationship with AstraZeneca Canada Ltd; 24 months; Speaker/Speaker's Bureau relationship with AstraZeneca Canada Ltd; 24 months
Branson, Richard (RRT, FAARC)	Scientific Medical Advisor relationship with Lung Pacer LLC; 6/2021-present
Brown, Jeanette (PhD, MD, FCCP)	Speaker/Speaker's Bureau relationship with Breas; 08/20/24

Brown, Kevin (MD, FCCP)	Advisory Committee Member relationship with Boehringer Ingelheim; 2019-2023; DMC relationship with Humanetics; 2020-2023; Consultant relationship with Bristol Myer Squibb; 2017-2023; Consultant relationship with Fibrocor Therapeutics; 2023; Consultant relationship with AbbVie; 2023; Consultant relationship with Huitai Biomedicine; 2019-2020; Consultant relationship with Astra Zeneca; 2023; Consultant relationship with Galecto; 2013-2023; Consultant relationship with Variant Bio; 2025; Advisory Committee Member relationship with Galapagos; 2017-2023; Consultant relationship with Vertex; 2023-2025; Consultant relationship with GSK; 2025; Consultant relationship with CSL Behring; 2019-2023; Board Member relationship with Fleischner Society; 2021-2025; Consultant relationship with Avalyn Pharma; 2024-2025; Consultant relationship with Eleven P15; 2020-2023; Consultant relationship with Dispersol; 2019-2020; Advisory Committee Member relationship with DevPro Pharma; 2021-2023; Advisory Committee Member relationship with Trevi Therapeutics; 2022-2023; Consultant relationship with Syndax; 2025; DMC relationship with Scleroderma Research Foundation; 2023; Board Member relationship with OSIC; 2019-2023; Consultant relationship with Cumberland Pharma; 2021; Consultant relationship with Sanofi; 2022-2023; Consultant relationship with Redx Pharma; 2021-2022
Buddhdev, Bhuvin (MD, FCCP)	Advisory Committee Member relationship with liquidia; feb 2025; Advisory Committee Member relationship with Janssen; Dec 2023, Dec 2024; Advisory Committee Member relationship with Liquidia corporation; Feb 2025; Advisory Committee Member relationship with united therapeutics; june 2023; Advisory Committee Member relationship with janssen; dec 2023 dec 2024
Callahan, Sean (MD, FCCP)	Advisory Committee Member relationship with Gilead; November 2023
Casal, Roberto (MD, FCCP)	Research Grants relationship with Intuitive Surgical; Current; Consultant relationship with Siemens; Current; Research Grant relationship with Johnson and Johnson; Current
Case, Amy (MD, FCCP)	Site investigator relationship with United Therapeutics; current; Site investigator relationship with Avalyn; current; Site investigator relationship with Genentech / Roche; ended; Site investigator relationship with Boehringer Ingelheim; current; Site investigator relationship with Puretech Health; current

Castro, Mario (MD, FCCP)	Consultant relationship with Kinaset; 1-2023 to present; Speaker/Speaker's Bureau relationship with MedLearningGroup; 2+years; Consultant relationship with Amgen; 5years; Site investigator relationship with Nocion; 1+year; Consultant relationship with Upstream Bio; 4-2024 to present; Consultant relationship with Jasper Therapeutics; 4-2024 to present; Consultant relationship with Genentech; 2+years; Principal Investigator relationship with Genentech; 5 years; Consultant relationship with Blueprint Medicines; 1-2024 to present; Advisory Committee Member relationship with Pfizer; 5 years; Consultant relationship with Verona Pharmaceuticals; 10-2023 to present; Consultant relationship with Uniquity Bio; Jan 2025 to present; Consultant relationship with Generate Biomedicines; 2-2024 to present; Consultant relationship with Apreo Health; 7-2024 to present; Advisory Committee Member relationship with Polarean; 1-2025 to present; Advisory Committee Member relationship with Enveda; 2-2025 to present; Consultant relationship with AstraZeneca; 2+years; Consultant relationship with Apogee; 4-2024 to present; Consultant relationship with Aer Therapeutics; Jan 2023-present; Principal Investigator relationship with AstraZeneca; Ongoing; Speaker/Speaker's Bureau relationship with AstraZeneca; Ongoing; Principal Investigator relationship with Novartis; Ongoing; Consultant relationship with Novartis; Ongoing; Principal Investigator relationship with GSK; Ongoing; Consultant relationship with GSK; Ongoing; Principal Investigator relationship with Sanofi-Aventis; Ongoing; Speaker/Speaker's Bureau relationship with Sanofi-Aventis; Ongoing; Consultant relationship with Sanofi-Aventis; Ongoing; Speaker/Speaker's Bureau relationship with Teva; Ongoing; Speaker/Speaker's Bureau relationship with Genentech; Ongoing; Consultant relationship with Genentech; Ongoing; Consultant relationship with Third Rock Ventures; 1-2024 to present; Consultant relationship with TEVA; 5+years; Speaker/Speaker's Bureau relationship with Regeneron; Ongoing; Principal Investigator relationship with Shionogi; Ongoing; University Study Grant relationship with Pulmatrix; ongoing; Consultant relationship with Merck; ongoing; Speaker/Speaker's Bureau relationship with Amgen; ongoing; Principal Investigator relationship with GALA Therapeutics; 1-21-2020 to present; Principal Investigator relationship with Theravance; Jan 2023-Present; Consultant relationship with Arrowhead Pharmaceuticals; Jan 2023-present; Consultant relationship with Allakos; Jan 2023-present; Consultant relationship with Om Pharma; Jan 2023-present; Consultant relationship with Pioneering Medicines; Jan 2023-present; Site investigator relationship with PCORI; 5+ years
Cavallazzi, Rodrigo (MD)	Site investigator relationship with AstraZeneca; 08/07/2025; Consultant relationship with Pfizer; One-time (01/11/2024)
Chalmers, James	Consultant relationship with Insmed; 2020-2025; Consultant relationship with Insmed; 2022-2025

Chaudary, Nauman (MBBS, FCCP)	Advisory Committee Member relationship with PARI; 2019; Consultant relationship with Insmed; 10/09/2023; Consultant relationship with GRG Health; 03/06/2024; Consultant relationship with MJH Lifesciences; 03/07/2024; Moderator relationship with PARI; 2021; Advisory Committee Member relationship with DYMEDSO; 2021
Chen, Alex (MD)	Consultant relationship with Olympus; 2020-2023; Consultant relationship with Olympus; 2022-2023; Investigator relationship with Olympus; 2022-2023; Consultant relationship with Apreo; 2023-2024; Consultant relationship with Biodesix; 2022-2023
Chorostowska-Wynimko, Joanna (PhD, MD)	congress support relationship with Johnson&Johnson; 2024-2025; Advisory Committee Member relationship with Astra Zeneca; 2024-2025; Speaker/Speaker's Bureau relationship with MSD; 2024-2025; Speaker relationship with Chiesi; 2024-2025; Consultant relationship with Amgen; 2024-2025
Chou, Sherry (MD)	Grant receipt (principal investigator relationship with The Neurocritical Care Society; Ongoing; Advisory Committee Member relationship with Grace Therapeutics; Ongoing; Consultant relationship with TD securities; 2025
Cicenia, Joseph (MD, FCCP)	Consultant relationship with BodyVision; 2020 to 2023; Consultant relationship with bodyvision; 2022; Scientific Medical Advisor relationship with Noah Medical; 2023-2024; Scientific Medical Advisor relationship with Noah Medical; Jan 2024 to present
Coleman, John (MD)	Advisory Committee Member relationship with ResMed; 5/2021-12/2025
Collop, Nancy (MD, Master FCCP)	Advisory Committee Member relationship with Incannex; 7/1/2025 - 8/31/2025; Consultant relationship with Zoll Respircardia; 1/1/2025-current; Advisory Committee Member relationship with Apnimed; 5/2025 - current; Consultant relationship with Huxley; October 2025-current; Grant support relationship with zoll; 9/1/2024 - 8/31/2028; Research support relationship with Huxley; 09012021
Corbridge, Susan (PhD, ACNP, FCCP)	spouse is employed by GSK relationship with GlaxoSmithKline; >\$100000
Courtwright, Andrew	Research support relationship with Sanofi Genzyme; 6/1/2023-12/13/2024
D'Ambrosio, Carolyn (MS, MD, FCCP)	Consultant relationship with Dynamed; 2020-present
Dalal, Bhavinkumar (MD, MBBS, FCCP)	Consultant relationship with INARI; 10/01/2024 to 12/31/; Speaker/Speaker's Bureau relationship with AstraZeneca; 8/22/23 to 12/31/25

Daley, Charles (MD, FCCP)	Advisory Committee Member relationship with Insmed; 2014-present; Consultant relationship with Akagera; 2024-present; Advisory Committee Member relationship with AN2; 2019-present; Advisory Committee Member relationship with Spero; 2015-present; Research Grant relationship with AN2; 2022-present; Research Grant relationship with Paratek; 2022-present; Advisory Committee Member relationship with Paratek; 2015-present; Advisory Committee Member relationship with Matinas; 2018-present; Scientific Medical Advisor relationship with Genentech; 2021-present; Advisory Committee Member relationship with Galapogos; 2024-present; Advisory Committee Member relationship with Hyfe; 2022-present; Research Grant relationship with BugWorks; 2021-present; Advisory Committee Member relationship with Aztrazeneca; 2021-present; Research Grant relationship with Insmed; 2014-present; Advisory Committee Member relationship with Otsuka; 2022-present; Advisory Committee Member relationship with Nob Hill; 2020-present; Scientific Medical Advisor relationship with Pfizer; 2021-present; Research Grant relationship with Juvabis; 2022-present
Daley, Lauren (MD)	Shareholder - Public relationship with BioCryst; 5/23-present
Daniels, M. Leigh Anne (BA, MPH, MD)	PI for clinical trial relationship with MannKind; 7/2025 to present
Davies, John (MA, RRT, FCCP)	Consultant relationship with Teleflex Medical; 2014 to present; Speaker/Speaker's Bureau relationship with MedBridge Education; 6/2022 - present
de Angelis, Paolo	Attended paid training course relationship with Intuitive; 1/29/25, 1day only
Debiane, Labib (MD, FCCP)	Consultant relationship with Intuitive Surgical; 05/21/2024; Consultant relationship with Elucent Medical; 10/2023-10/2024
Dell, Sharon	Clinical trial PI relationship with Sanofi Aventis Canada Inc; 01-2024-; Clinical trial stie PI relationship with Boehringer Ingelheim Canada Ltd; 01-2024-; Consultant relationship with Regeneron Pharmaceuticals Inc; 01-2024-12-2025; Speaker/Speaker's Bureau relationship with Sanofi Benzyme Corporation; 01-2024-12-2025; Advisory Committee Member relationship with Sanofi Aventis Canada Inc; 01-2024-12-2025; Sub-investigator for clinical trials relationship with Vertex Pharmaceuticals; 01-2024:
Denlinger, Loren (PhD, MD)	Advisory Committee Member relationship with OM Pharma; June 2022, Dec 2023
Desai, Alpa (BS, MD, FCCP)	Speaker/Speaker's Bureau relationship with Boehringer Ingelheim; 2021 to present

Dhand, Rajiv (MBBS, MD, FCCP)	author relationship with Taylor and Francis Publishers; 2023 - present; Advisory Committee Member relationship with Genentech; 2025; Consultant relationship with Verona; 2023; Consultant relationship with Viartis; 2022 to present; Consultant relationship with Theravance; 2021 to present; Consultant relationship with Mylan; 2020; author relationship with UpToDate; 2018 to present
Dilling, Daniel (MD, FCCP)	Advisory Committee Member relationship with United Therapeutics; 2022; clinical trial relationship with United Therapeutics; 2024; Advisory Committee Member relationship with Boehringer Ingelheim; 2025; clinical trial relationship with Boehringer Ingelheim; 2024; Speaker/Speaker's Bureau relationship with Boehringer Ingelheim; 2024
DiSilvio, Briana (MD)	Speaker/Speaker's Bureau relationship with Boehringer-Ingelheim; Sept 2021-Present; Speaker/Speaker's Bureau relationship with AstraZeneca; Jan 2023- present; Speaker/Speaker's Bureau relationship with GlaxoSmithKline; Jan 2024- present; Researcher relationship with Boehringer-Ingelheim; May 2023 - Present; Researcher relationship with Regeneron; Oct 2023-Present; Speaker/Speaker's Bureau relationship with Verona Pharma; Aug 2024 - present
Donington, Jessica (MD, MS)	Scientific Medical Advisor relationship with Lilly; 2/2025; speaker relationship with AstraZenca; 1/2020-present; speaker relationship with BMS; 1/2020-present; speaker relationship with Merck; 1/2020-present; Scientific Medical Advisor relationship with Amgen; 2/2024; speaker relationship with Roche/Genentech; 1/2020-present
Dubowski, Kathryn (MD)	Consultant relationship with Regeneron; 5/1/2024- 5/31/2024
Dubrock, Hilary (MD)	Grant/researchsupport relationship with Bayer; 2021-2024; Consultant relationship with Janssen; 2020-2024; Advisory Committee Member relationship with Janssen; 2023-2024; Advisory Committee Member relationship with Merck; 2024; Consultant relationship with Merck; 2023-2025; Speaker/Speaker's Bureau relationship with United Therapeutics; 2023-2024
Dulohery Scrodin, Megan (MD)	Advisory Committee Member relationship with Sanofi; 11/12/2024; Speaker/Speaker's Bureau relationship with Regeneron; May 2024; Investigator relationship with Astra Zeneca; 2022-present
Dumont, Tiffany (DO, FCCP)	co-PI relationship with BI; 1/2023-ongoing; PI relationship with Regeneron; 10/2023-ongoing; Speaker/Speaker's Bureau relationship with GSK; 2/2025-ongoing; Advisory meeting relationship with Verona Pharma; April 2023

Eckert, Danny (PhD)	Research grants relationship with Bayer; 2016-2023; Consultant relationship with Mosanna; 2022-; Research grants and consultant relationship with Apnimed; 2018-; Research grants relationship with Eli Lilly; 2022-; Research grants relationship with Restera (formally Invicta Medical); 2021-; Research grant relationship with Restora; 2025-; research grant relationship with Withings; 2022; research grant relationship with Takeda; 2021-; Advisory Committee Member relationship with ResSleep; 2025-
El-Kersh, Karim (MD)	Consultant relationship with United Therapeutics; Current; Advisory Committee Member relationship with United Therapeutics; Current; Advisory Committee Member relationship with Merck; Current; Consultant relationship with United Therapeutics; Current; Consultant relationship with Merck; Current; Advisory Committee Member relationship with Merck; Current; Advisory Committee Member relationship with J&J Actelion; Current; Advisory Committee Member relationship with United Therapeutics; Current; Consultant relationship with Merck; Current; Consultant relationship with J&J; Current
Esposito, Anthony (MD, FCCP)	Advisory Committee Member relationship with United Therapeutics; 09/30/25 - 11/07/25; Speaker/Speaker's Bureau relationship with Boehringer Ingelheim; 09/29/25 - Present
Fan, Eddy (PhD, MD)	Consultant relationship with Baxter; 2020-present; Advisory Committee Member relationship with Inspira; 2020-present; Advisory Committee Member relationship with Vasomune; 2019-present; Consultant relationship with Aerogen; 2024-present; Consultant relationship with Getinge; 2022-present; Advisory Committee Member relationship with Boehringer Ingelheim; 2024-present
Farber, Harrison (MD)	Advisory Committee Member relationship with Aerovate; ~1yr (to present); Advisory Committee Member relationship with Actelion (Janssen); several years to pre; Advisory Committee Member relationship with Atlavant; ~2yrs (to present); Advisory Committee Member relationship with Acceleron (Merck); ~3years (to present); Advisory Committee Member relationship with United Therapeutics; many years (to pre; Advisory Committee Member relationship with Aerami; 12mo to present; Consultant relationship with Keros; started 11/15/23; Consultant relationship with Pulmovant; march 2024 to present
Faugno, Anthony (MD)	Consultant relationship with Moderna; 08/2020-05/2023; Meeting Expenses relationship with Sedana; 5/2025
Feller-Kopman, David (MD, FCCP)	Consultant relationship with Fujifilm; 2023-present; Consultant relationship with Merit; 2023-present; Section Editor relationship with UpToDate; ongoing
Flume, Patrick (MD)	Research relationship with Spero; 2022-2024; Research relationship with Boehringer-Ingelheim; 2023-ongoing; Research relationship with Insmed; 2020-ongoing; Research relationship with Paratek; 2022-ongoing

Foer, Dinah	Advisory Committee Member relationship with Eli Lilly; June 2025
Foldvary-Schaefer, Nancy (DO)	Scientific Medical Advisor relationship with American Parkinson's Disease Association; 2024-2025; Scientific Medical Advisor relationship with Oxford University Press; 2010-2025; Scientific Medical Advisor relationship with UpToDate; 2010-2025; Advisory Committee Member relationship with Jazz Pharmaceuticals; 2024-2025; Scientific Medical Advisor relationship with Jazz Pharmaceuticals, Takeda, Suven, Avadel, Vanda, Alkermes; 2010-2025
Ford, H. James (MD)	Consultant relationship with Janssen; 1 day; Consultant relationship with Gossamer Bio; 1 day; Consultant relationship with Merck; 2 separate days; Consultant relationship with United Therapeutics; 2 separate days; Consultant relationship with Liquidia; 1 day
Fox, Adam (M.Sc, MD)	Grant recipient relationship with Amgen; 2022-2024; Consultant relationship with Olympus Corporation of America; Fall 2025; stockholder relationship with MMM; \$20001 - \$100000; stockholder relationship with Merck; \$20001 - \$100000; Consultant relationship with Astra Zeneca; 2/2025; Grant recipient relationship with Astra Zeneca; 2024
Franco, Veronica (MSPH, MD, FCCP)	Consultant relationship with Gossamer; March 2024; Consultant relationship with Merck; October 2024
Garwood, Susan (MD)	Speaker/Speaker's Bureau relationship with Intuitive; 2023-present; Advisory Committee Member relationship with Circulogene; 2024-present; Speaker/Speaker's Bureau relationship with Galvanize; 2025; Speaker/Speaker's Bureau relationship with Biodesix; 2020-present
Geistkemper, Anne	Speaker/Speaker's Bureau relationship with Sentec; 09/2022-present; Consultant relationship with Maxtec; 7/2023-present; Speaker/Speaker's Bureau relationship with Fisher & Paykel; 10/2023-present
George, Peter (MBBS BSc PhD FRCP)	Speaker/Speaker's Bureau relationship with Roche Pharmaceuticals; 2017 - 2021; Advisory Committee Member relationship with Daiichi-Sankyo; 2023; Advisory Committee Member relationship with AstraZeneca; 2022 - 2024; Speaker/Speaker's Bureau relationship with Cipla; 2021; Advisory Committee Member relationship with GSK; 2023 to current; Senior Medical Director relationship with Brainomix; 2020 to current; Speaker/Speaker's Bureau relationship with Boehringer Ingelheim; 2018 to 2023; Speaker/Speaker's Bureau relationship with Boehringer Ingelheim; 2017 to 2024; Research grant recipient relationship with Boehringer Ingelheim; 2021 to current
Giannini, Heather (MD)	Consultant relationship with Inogen; Feb 2025-present
Giri, Paresh (MD, FCCP)	Speaker/Speaker's Bureau relationship with United Therapeutics; 4 years

Glassberg, Marilyn (MD, FCCP)	Advisory Committee Member relationship with Structure Therapeutics; 2023-present; Advisory relationship with Bristol Myers Squibb; 2022-present; MKG serves as the DSMB co-chair of Redx relationship with Red-X; 2022-present
Gomberg Maitland, Mardi (MD)	Consultant relationship with aeromi; 2022-present; Consultant relationship with Keros; 2023-present; PI- GWU MFA relationship with aerovate; 2022-7/2024; Grant review relationship with United therapeutics; 2020 to present; PI- GWU MFA relationship with merck/acceleron; 2021 to present; Consultant relationship with united therapeutics; 2021 to present; Consultant relationship with United Therapeutics; present; Steering Committee relationship with Merck; present; Consultant relationship with Keros; 2023; Steering Committee relationship with Janssen; completed 9/23; Board of Directors relationship with ISHLT; 2021-present; Advisory Committee Member relationship with Actelion/Janssen; 2020 to present; Scientific Medical Advisor relationship with Acceleron/Merck; 2019-present; Scientific Medical Advisor relationship with united therapeutics; 2016 to present; Research grant GW relationship with Gossamer; March 2024
Gong, Michelle (MD)	Scientific Medical Advisor relationship with regeneron; 1 year in 2023; Scientific Medical Advisor relationship with novartis; 5/23/24 to 5/24/24; Consultant relationship with radiometer; 3/19/24 for 1 day
Goyal, Amit (MD)	Consultant relationship with Intuitive Surgical; 1/1/2023-present
Gray, Alice (MD)	Advisory Committee Member relationship with Kamada; October 2024; Advisory Committee Member relationship with TFF Pharmaceuticals; February 2024; Speaker/Speaker's Bureau relationship with CareDx; March-April 2024
Gray, Sarah (MD)	Advisory Committee Member relationship with Sanofi; 4/27/24;3/18/25;10/1; Advisory Committee Member relationship with AstraZeneca; 9/12-9/13; 10/18
Green, O Neil (MBBS)	Principal Investigator - ENCORE trial relationship with Insmed; 12/2021 - present; Expert Contributor relationship with BMJ Best Practice; 5/20/2022 - present; Principal Investigator relationship with Insmed Inc; 12/3/2021 - present; Principal Investigator relationship with Insmed Inc; 7/2/2019 - present; Consultant relationship with Pharming Inc; 7/26/24; Principal Investigator relationship with PCORI; 2018-; Consultant relationship with BMJ Best Practice; 2022- present
Gupta, Amit	Advisory Committee Member relationship with Qure.AI; 06/12/2025 - Present; Advisory Committee Member relationship with Flutespace LLC; 02/21/2024 - present; Consultant relationship with GE Healthcare; 12/08/2023 to 12/28/; Advisory Committee Member relationship with PictureHealth.AI; 2022-Present

Gupta, Rohit (MD, MBBS, FCCP)	Institutional grant relationship with aTyR; 6/2023-ongoing; Advisory Committee Member relationship with UT; 8/2023; Institutional grant relationship with Molecure; 2023-ongoing; Institutional grant relationship with Xentria; 2023-ongoing; Consultant relationship with Incyte; 2024-ongoing; Advisory Committee Member relationship with ANI; 9/2023, 10/2024; Institutional grant relationship with Kinevant; 3/2023-ongoing; Speaker/Speaker's Bureau relationship with MNK; 5/2023-ongoing
Hadeh, Anas (MD)	Speaker/Speaker's Bureau relationship with Verona; 12 months; Advisory Board relationship with Insmed; 12 months
Halpern, Neil (MD, FCCP)	Advisory Committee Member relationship with Pronia Medical; \$1001 - \$5000
Hamblin, Mark (MD)	Principal Investigator Research Grant relationship with Bristol Meyers Squibb, Inc; 24 months; Speaker/Speaker's Bureau relationship with Boehringer Ingelheaim, Inc; 96 months; Advisory Committee Member relationship with Boehringer Ingelheim, Inc; 24 months; Advisory Committee Member relationship with Avalyn Pharmaceuticals, Inc; 1 month; Principal Investigator Research Grant relationship with United Therapeutics, Inc; 24 months; Principal Investigator Research Grant relationship with Vicore Pharmaceuticals; 8 months; Principal Investigator Research Grant relationship with Atyr Pharmaceuticals; 10 months; Advisory Committee Member relationship with Trevi Pharmaceuticals; 1 month; Principal Investigator Research Grant relationship with CSL Behring, Inc; 14 months; Principal Investigator Research Grant relationship with Boehringer Ingelheim, Inc; 96 months; Principal Investigator Research Grant relationship with Kinevant, Inc; 18 months; Principal Investigator Research Grant relationship with Horizons, Inc; 14 months; Principal Investigator Research Grant relationship with Avalyn Pharmaceuticals, Inc; 2 months; Principal Investigator Research Grant relationship with Novartis, Inc; 9 months; Principal Investigator Research Grant relationship with Genentech, Inc; 24 months; Principal Investigator Research Grant relationship with Puretech, Inc; 10 months; Principal Investigator Research Grant relationship with Daewoong Pharmaceuticals, Inc; 10 months; Principal Investigator Research Grant relationship with Pliant Pharmaceuticals; 4 months; Advisory Committee Member relationship with United Therapeutics, Inc; 24 months

Han, MeiLan (MD, FCCP)	Consultant relationship with GSK; ongoing; Consultant relationship with Genentech/Roche; ongoing; Consultant relationship with Amgen; Ongoing; Research support relationship with Sunovion; ongoing; Board Member relationship with Cipla; within the last year; Consultant relationship with Chiesi; within the last year; Consultant relationship with AZ; ongoing; Consultant relationship with GSK; ongoing; Consultant relationship with Verona; within the last year; Consultant relationship with Merck; Within the last 2 yr; Consultant relationship with AstraZeneca; ongoing; Consultant relationship with Sanofi; ongoing; Consultant relationship with Sanofi; ongoing; Consultant relationship with DevPro; within the last 2 yr; Consultant relationship with Aerogen; within 2 years; Consultant relationship with Amgen; within 2 years; sponsored research relationship with Altesa; ongoing; sponsored research relationship with Nuvaaira; ongoing; sponsored research relationship with AZ; ongoing; sponsored research relationship with Sanofi/Regeneron; ongoing; sponsored research relationship with BI; ongoing; sponsored research relationship with Gala therapeutics; ongoing; sponsored research relationship with Biodesix; ongoing; DSMB relationship with Medtronic; ongoing; DSMB relationship with Novartis; ended; Consultant relationship with Meissa Vaccines; ongoing; Consultant relationship with Altesa; ongoing; Advisory Committee Member relationship with Altesa; Ongoing; Speaker/Speaker's Bureau relationship with Chiesi; 2021; Speaker/Speaker's Bureau relationship with Cipla; 2021; Consultant relationship with Regeneron; ongoing; Consultant relationship with DevPro; 2021; Advisory Committee Member relationship with Polarian; 2021; Consultant relationship with Aerogen; 2021; Advisory Committee Member relationship with Meissa Vaccines; Ongoing; Advisory Committee Member relationship with Altesa; Ongoing; Consultant relationship with Verona; 2020; Consultant relationship with Pulmonx; 2021; Consultant relationship with Novartis; 2021; Advisory Committee Member relationship with Merck; 2021; Consultant relationship with Cipla; 2020; Consultant relationship with Chiesi; 2020; Consultant relationship with AZ; ongoing
Hanania, Nicola (MD, MS, FCCP)	Research support relationship with Sanofi Genzyme and Genentech; 2020-2021; Research support relationship with Boehringer Ingelheim, GSK, Novartis; 2020-2021; Advisory Committee Member relationship with Regeneron, Amgen, and Teva; 2020-2021; Consultant relationship with AstraZeneca, Genentech, GSK, Mylan, Sanofi; 2020-2021; Advisory Committee Member relationship with AstraZeneca, Genentech, GSK, Mylan, Sanofi; 2020-2021
Hays, Steven	Advisory Committee Member relationship with Mallinckrodt Pharmaceuticals; 1/1/2023-1/1/2024; Advisory Committee Member relationship with CareDx; 1/1/2021-8/30/2023

Henkle, Emily	Consultant relationship with Spero; 2024; Advisory Committee Member relationship with MannKind; 2022-2023; Advisory Committee Member relationship with AN2; 2020-2024
Hossri, Sami (MD)	Advisory Committee Member relationship with Verona; 2024; Advisory Committee Member relationship with Sanofi; 2024
Hou, Cindy	Advisory Committee Member relationship with Sepsis Alliance; 2024-2025, completed for PCORI project and was advisory board member; Chief Medical Officer for Sepsis Alliance, member of Board of Directors; Speaker/Speaker's Bureau relationship with Sanofi; Completed; HAI Advisor, Medical Diversity relationship with Abbott; 2023-present; Scientific Medical Advisor relationship with Peggy Lillis Foundation; 2024-present; Principal Investigator -grant relationship with Office of Minority Health; 2022-current; Co-editor of a book, chapter co-author relationship with Elsevier; 2023-ongoing
Hu, Kurt (MD)	Speaker/Speaker's Bureau relationship with Sanofi/Rageneron; 8/12/2025; Consultant relationship with AstraZeneca; 5/1/2025; Speaker/Speaker's Bureau relationship with Verona Pharmaceutical; 8/1/2024
Iams, Wade	Advisory Committee Member relationship with Novartis; February 2025; Advisory Committee Member relationship with EMD Serono; June 2025; Advisory Committee Member relationship with AstraZeneca; February 2025; Advisory Committee Member relationship with Genentech; February 2025; Speaker/Speaker's Bureau relationship with Jazz Pharma; Ongoing; Speaker/Speaker's Bureau relationship with NovoCure; Ongoing; Speaker/Speaker's Bureau relationship with Amgen; Ongoing; Advisory Committee Member relationship with Merus; November 2023; Advisory Committee Member relationship with Bristol Myers Squibb; November 2023
Janz, David (MSc, MD)	Consultant relationship with CytoVale; 2019 - present
Javaheri, Shahrokh (MD, FCCP)	Consultant relationship with respicardia; upto present; Speaker/Speaker's Bureau relationship with Avadel and Idorsia Phamaceutical companies; 2 years
Johri, Shilpa (MD, FCCP)	Research Grant relationship with United Therapeutics; 2019 - Ongoing; Research Grant relationship with Bellephoron Pharmaceuticals; 2017 - 2021; Research Grant relationship with Janssen; 2019-2021; Research Grant relationship with Bayer Pharmaceuticals; 2018 - 2021; Research Grant relationship with Acceleron; 2021- ongoing
Kapp, Chris (MD)	Consultant relationship with Intuitive; 4/2024-current; Consultant relationship with Intuitive; 4/2024-present; Proctoring for bronchoscopy relationship with Intuitive; 8/2023-present

Katz, Sherri (MD, FCCP)	Chair, Home Mechanical Ventilation assem relationship with Canadian Thoracic Society; 2022-2025; Speaker/Speaker's Bureau relationship with Parent Project Muscular Dystrophy; 2024; Vice- Chair, Sleep Network relationship with CHEST; 2024-2025; Research grant recipient relationship with Children's Hospital of Eastern Ontario Research Institute; 2019-2025; Research grant recipient relationship with Canadian Institutes of Health Research; 2023-2029; Research grant recipient relationship with Physician Services Incorporated; 2019-2025; Research grant recipient relationship with CHEST foundation; 2022-2024; Research grant recipient relationship with CHAMO Research Fund; 2019-2025
Keane, Florence (MD)	Speaker relationship with IASLC; 2023 - present; Editor relationship with UpToDate; 2019 - present
Kelly, Bryan (DO, FCCP)	Advisory Committee Member relationship with United Therapeutics; July 2025
Keogh, Karina (MBBCh, FCCP)	Educational grant relationship with GSK/Potomac Center for Medical Education (PCME),; 2019-2020; Site PI for pharmaceutical trial relationship with AstraZeneca; 2022; monograph relationship with BMJ; \$1-\$1000; Consultant relationship with Astra Zeneca; 2023-2024; Advisory Board relationship with Kenvue; 2024
Khabbaza, Joseph (MD)	Speaker/Speaker's Bureau relationship with Sanofi/Regeneron; 6/2023 to present; Speaker/Speaker's Bureau relationship with Insmed; 10/2018 to present; Advisory Committee Member relationship with Baxter; 4/2025 to present; Consultant relationship with Tactile; 1/2024 to present; Advisory Committee Member relationship with Insmed; 10/2018 to present
Khan, Akram (MD, MBBS, FCCP)	Site PI relationship with Ely Lilly; 2021-2022; Site PI relationship with Direct Biologics; 2023-2025; Consultant relationship with Dompe Pharmaceuticals; 2022; Site PI relationship with 4D Medical; 2021-2023; Site PI relationship with Glaxo Smith Kline; \$20001 - \$100000; Site PI relationship with Reata Pharmaceuticals; \$20001 - \$100000; Site PI relationship with United Therapeutics; \$20001 - \$100000; Site PI relationship with Johnson & Johnson / Actelion; \$20001 - \$100000
Kher, Sucharita (MD, FCCP)	Beneficiary of exercised stock options relationship with Linus health; since 2020; Beneficiary of stock relationship with SiPhox; since 2023; Beneficiary of stock relationship with Generate Biomedicine; since 2023; Board Member relationship with American lung association, MA leadership board; Since 9/2024
King, Christopher (MD, FCCP)	Speaker/Speaker's Bureau relationship with United Therapeutics; 2021- present; Advisory Committee Member relationship with United Therapeutics; 2022; Speaker/Speaker's Bureau relationship with United Therapeutics; 2021 to present; Speaker/Speaker's Bureau relationship with United Therapeutics; 2021-present

Kingrey, John (MD)	Speaker/Speaker's Bureau relationship with Merck; Started 4/1/24; Speaker/Speaker's Bureau relationship with Bayer Pharmaceuticals; \$1001 - \$5000; Speaker/Speaker's Bureau relationship with Actelion J&J; \$5001 - \$20000; Consultant relationship with Liquidia; started 4/1/24; Speaker/Speaker's Bureau relationship with United Therapeutics; \$5001 - \$20000
Kolaitis, Nicholas (MD)	Consultant relationship with Merck; 11/2025; Consultant relationship with Johnson & Johnson; 6/2024; Consultant relationship with United Therapeutics; 8/2025; Consultant relationship with Liquidia; 2/2025; Consultant relationship with Gossamer; 5/2024
Kraft, Monica (MD, FCCP)	Board Member relationship with Genentech; 2023-present; Speaker/Speaker's Bureau relationship with Chiesi; 2023-present; Speaker/Speaker's Bureau relationship with Regeneron; 2023-2024; Advisory Committee Member relationship with Kinaset; 2023-2024; Consultant relationship with Chiesi; 2021-2022; Grant relationship with ALA; 10 years; Consultant relationship with Sanofi-Regeneron; 2022-present; Consultant relationship with Astra-Zeneca; 2023-present; Grant relationship with NIH; 20 years
Krantz, Seth (MD)	Travel for training relationship with Intuitive surgical; 8/1/25; Shareholder - Private relationship with Novascan; 1/1/2025-current
Krishnan, Jerry (MD)	Consultant relationship with MedImmune; 2025-present; Consultant relationship with Verona Pharma; 2024; Consultant relationship with Dynamed; 2024-present; Board Member relationship with Global Initiative for Asthma; 2015- present; Consultant relationship with AstraZeneca; 2021 to 2025; Consultant relationship with BData, Inc; 2021 to 2023
Kulkarni, Tejaswini (MD, MPH, FCCP)	Consultant relationship with PureTech Inc; 11/2023 - 11/2024; Consultant relationship with United Therapeutics Inc; 04/2022 - 12/30/2025; Consultant relationship with Mediar; 4/10/24 - 4/10/25; Speaker/Speaker's Bureau relationship with Veracyte; 08/2023- 08/2024; Consultant relationship with Aileron/ Lung; 2/1/2024 - 3/1/2024; Consultant relationship with Boehringer Ingelheim; 01/01/24 - 11/15/26; Consultant relationship with Tempus; 10/1/2024- 9/30/2025; Advisory Board relationship with Avalyn; 6/1/2024- 5/31/2025; Consultant relationship with Brainomix; 03/1/2025 - 3/12/25; Consultant relationship with Vicore; 12/2024 - Current
Kumar, Anupam (MD, FCCP)	Consultant relationship with Clario; 05/2024-; Speaker/Speaker's Bureau relationship with Boehringer Ingelheim; 11/2024-
Kuperberg, Stephen (MD)	Consultant relationship with Merck; 10/2024 - present

Kurman, Jonathan (MBA, MD, FCCP)	Consultant relationship with Ambu; 2021-present; Consultant relationship with Pulmonx; 2020 - present; Consultant relationship with Medtronic; 2020 - present; Consultant relationship with Cook Medical; 2021 - present; Speaker/Speaker's Bureau relationship with Biodesix; 2018 - present; Speaker/Speaker's Bureau relationship with Veracyte; 2021-present; Consultant relationship with Noah Medical; 2023-present; Consultant relationship with Pinnacle Biologics; 2020 - present; Advisory Committee Member relationship with Circulogene; 2024-present; Consultant relationship with Verathon; 2023-present; Speaker/Speaker's Bureau relationship with Verona Pharma; 2024-present; Consultant relationship with Merit; 2022-present; Consultant relationship with Galvanize; 2023-present
La Vita, Carolyn (MHA, RRT)	Consultant relationship with VERO Biotech; Jan 2024; Speaker relationship with Massachusetts Society for Respiratory Care; 2020-current; Advisory Committee Member relationship with Nihon Kohden; 2021-current; Committee Member relationship with American Association for Respiratory Care; 2019-current; Advisory Committee Member relationship with Mallinckrodt; 2025-current; Consultant relationship with Timpel; Nov 2023
Lachowicz, Ashley (AE-C, MSc, RRT-ACCS)	Speaker/Speaker's Bureau relationship with AARC; 08/23 - 02/24; Advisory Committee Member relationship with Securisyn Medical; 08/21 - present
Lal, Chitra (MBBS, MD, FCCP)	Advisory Committee Member relationship with Axsome therapeutics; 5/1/2024-present; Consultant relationship with Idorsia Pharmaceuticals; 11/2022-present; Consultant relationship with Chest/GSK; 2021-2022; Advisory Committee Member relationship with Jazz Pharmaceuticals; Ongoing

Lancaster, Lisa (MD, FCCP)	PI following consultant relationship with BBT; ended March 2025; PI for research study relationship with boehringer ingelheim; ended 2024; PI following consultant relationship with Avalyn; ended March 2025; PI for research study relationship with bms; ending 3/31/25; Consultant relationship with Daewoong; 2020-2024; Consultant relationship with Structure Therapeutics; ended 2024; Advisory Committee Member relationship with United Therapeutics; 2020-feb 2025; Consultant relationship with DevProBiopharma; 2021- 3/31/25; Consultant relationship with Astrazeneca; 2021-3/31/25; Consultant relationship with OnCusp; ended march 2025; Consultant relationship with Daichii Sankyo; 2022-3/31/25; PI for research study relationship with pliant; 2015-3/31/25; PI following consultant relationship with avalyn; ended march 2025; Advisory Committee Member relationship with tvardi; ended march 2025; Consultant relationship with grifols; ended 2024; Consultant relationship with abbvi; ended feb 2025; PI relationship with gsk; ended march 2025; Consultant relationship with tempus; ended march 2025; Consultant relationship with JucaBio; ended March 2025; Consultant relationship with oxygenium; 2022- 3/31/25; Consultant relationship with PureTech; 2022-3/31/25; Advisory Committee Member relationship with tvardi; ended march 2025; Speaker/Speaker's Bureau relationship with boehringer ingelheim; ended 2024; Speaker/Speaker's Bureau relationship with veracyte; ended 2023; Consultant relationship with Pliant; 2021-jan 2025; Speaker/Speaker's Bureau relationship with united therapeutics; ended 2024
Lanz, Miguel (MD)	Consultant relationship with AZ; 2023-2025; Advisory Committee Member relationship with Cogent; 2023; Research relationship with AZ; 2023-2025; Consultant relationship with Sanofi Regeneron; 2023-2025; PI relationship with Sanofi Regeneron; 2023-2025; Advisory Committee Member relationship with Novartis; 2024; Speaker/Speaker's Bureau relationship with Amgen; 2024; Speaker/Speaker's Bureau relationship with Sanofi Regeneron; 2023-2025; Speaker/Speaker's Bureau relationship with AZ; 2023-2025; Research PI relationship with Genentech Roche; 2024-2025; Advisory Committee Member relationship with Genentech Roche; 2023; Advisory Committee Member relationship with Grifols; 2023
Lee, Frances (MD)	Advisory Committee Member relationship with Novartis; 2025; Owner/Founder relationship with BeaconDx, Inc.; 2024-2025; Advisory Committee Member relationship with BeBlo Pharma; 2020-2025
Lee, Y C Gary (PhD, MBChB, FCCP)	Support for clinical trials relationship with Rocket Med Plc; \$5001 - \$20000
Leikin, Scott (DO)	Consultant relationship with USMLE; 2024-2025; Consultant relationship with Werfen; 2024-2025

Leung, Grace	Consultant relationship with Theravance Biopharma; 12/5/2019-present
Li, Jie (RRT-ACCS, RRT, PhD, FCCM, FAARC)	Recipient of a research grant relationship with MEKICS Co. Ltd; within 24 months; Speaker/Speaker's Bureau relationship with Aerogen Ltd; within 24 months; Speaker/Speaker's Bureau relationship with Fisher & paykel healthcare Ltd; within 24 months; Speaker/Speaker's Bureau relationship with American association for respiratory care; within 24 months; section editor relationship with Respiratory care journal; within 24 months; Speaker/Speaker's Bureau relationship with Vincent Ltd; within 24 months; Recipient of a research grant relationship with Vincent Ltd; within 24 months; Recipient of a research grant relationship with American Association for Respiratory Care; within 24 months; Recipient of a research grant relationship with COPD foundation; within 24 months
lipworth, brian	Speaker/Speaker's Bureau relationship with AstraZeneca; 5 years; Consultant relationship with Bambusa; 1 year; Consultant relationship with Chiesi; 1 year; other relationship with AstraZeneca; 5 years; Advisory Committee Member relationship with AstraZeneca; 5 years; other relationship with Sanofi; 5 years; Advisory Committee Member relationship with Sanofi; 3 years; Speaker/Speaker's Bureau relationship with Sanofi; 5 years
Loor, Gabriel (MD, FCCP)	Scientific Medical Advisor relationship with Organvive; 12/2024-present; Investigator relationship with Transmedics; 2017-2024; Consultant relationship with Transmedics; 2022 -2024
Losier, Ashley (MD)	Advisory Committee Member relationship with Electromed; 10/13/24

Lugogo, Njira (MD)	Advisory Committee Member relationship with Amgen; Ongoing; Scientific Medical Advisor relationship with TEVA; Ongoing; Research relationship with Genentech; Ended 09/2022; Advisory Committee Member relationship with TEVA; Ongoing; Research relationship with TEVA; Ongoing; Research relationship with Novartis; Ended 08/2022; Advisory Committee Member relationship with AstraZeneca; Ongoing; Scientific Medical Advisor relationship with AstraZeneca; Ongoing; Grant support relationship with AstraZeneca; Ongoing; Consultant relationship with Avillion; May 2022-Dec 2022; Consultant relationship with TEVA; Ongoing; Speaking with my own content relationship with GSK; Ongoing; Consultant relationship with AbbVie; Ongoing; Grants relationship with Janssen; Ongoing; Grants relationship with SANOFI; Ongoing; Advisory Committee Member relationship with AstraZeneca; Ongoing; Advisory Committee Member relationship with Genentech; Ongoing; Advisory Committee Member relationship with GSK, Apogee, Foresee, Incyte; Ongoing; Grants relationship with GSK; Ongoing; Grants relationship with Genentech; 2021-2022; Grant fees relationship with Novartis; 2020-2022; Advisory Committee Member relationship with SANOFI; Ongoing; Grants relationship with TEVA; Ongoing; Advisory Committee Member relationship with TEVA; Ongoing; Grant support relationship with Avillion; 2019-2022; Speaker with my own slides relationship with AstraZeneca; Ongoing; Scientific Medical Advisor relationship with SANOFI; Ongoing; Grant fees relationship with Regeneron; Ongoing; Advisory Committee Member relationship with Regeneron; Ongoing; Consultant relationship with Avillion; May-Dec 2022; Grant support relationship with SANOFI; Ongoing; Not Speaker's Bureau relationship with GSK; Ongoing; Research money received by institution relationship with Janssen; 08/2020 - Present; Speaker/Speaker's Bureau relationship with GSK; Ongoing; Scientific Medical Advisor relationship with Regeneron; Ongoing; Non-speakers bureau relationship with Teva, GSK, SANOFI/Regeneron, Astra Zeneca; Ongoing; Research relationship with GSK; Ongoing; Speaker/Speaker's Bureau relationship with GSK; Ongoing; Advisory Committee Member relationship with SANOFI/Regeneron; Ongoing; Advisory Committee Member relationship with Nioxx; Ongoing; Scientific Medical Advisor relationship with Amgen; Ongoing; Advisory Committee Member relationship with Amgen; Ongoing; Funds for developing CME presentations relationship with AKH, Medscape and NACE; >24 months; Consultant relationship with AstraZeneca, TEVA, Avillion, GSK; >24 months; Clinical trial funding for institution relationship with AstraZeneca, Genentech, GSK, Regeneron, Sanofi, TEVA, Gossamer and Avillion; >24 months; Not Speaker's Bureau relationship with AstraZeneca; Ongoing; Advisory Committee Member relationship with AstraZeneca, Genentech, GSK, Novartis, Regeneron, Sanofi, Teva and Amgen; >24 months; Scientific Medical Advisor relationship with AstraZeneca; Ongoing; Research relationship with AstraZeneca; Ongoing; Research relationship with
----------------------------------	---

	SANOFI/Regeneron; Ongoing; Advisory Committee Member relationship with SANOFI/Regeneron; Ongoing; Not Speaker's Bureau relationship with AstraZeneca; Ongoing; Consultant relationship with AstraZeneca; Ongoing; Advisory Committee Member relationship with AstraZeneca, Sanofi, Teva, Regeneron, GSK; Ongoing; Advisory Committee Member relationship with Genentech; Ongoing; Consultant relationship with Avillion; Ongoing; Consultant relationship with GSK; Ongoing; Advisory Committee Member relationship with GSK; Ongoing
Ma, Kevin (MD)	Consultant relationship with Intuitive Surgical; 10/2/2023; Scientific Medical Advisor relationship with Verona; 11/2023; Research PI relationship with RightAir; 10/2023 to current; Consultant relationship with Pulmonx; 03/2023 to current; Consultant relationship with Pulmonx Corporation; 8/1/2023 - Current
MacIntyre, Neil (MD, Master FCCP)	Consultant relationship with Inogen; jan 2022; Consultant relationship with Inspirx Pharmaceuticals; 5 years
MacRosty, Christina (DO, FCCP)	Course director relationship with PulmonX; July 2022-June 2024
Maher, Toby (MD)	Consultant relationship with Insilico; 2023 - ongoing; Consultant relationship with Boehringer Ingelheim; 2020 - ongoing; Advisory Committee Member relationship with Puretech; 2024 onwards

Mahler, Donald (MD, FCCP)	Advisory Committee Member relationship with Viatris; October 2024; Advisory Committee Member relationship with AstraZeneca; February 2023; Advisory Committee Member relationship with BoehringerIngelheim; January 2023; Advisory Committee Member relationship with Verona; May 2023
Maier, Lisa (MS, MD, FCCP)	Grant support relationship with Foundation for Sarcoidosis Research; 2009-present; Written a chapter on CBD relationship with UpToDate; 2005-present; Advisory Committee Member relationship with Boehringer Ingelheim; 12/2022
Make, Barry (MD, FCCP)	Consultant relationship with Verona Pharma; 2023; Scientific Medical Advisor relationship with NHLBI; current; Scientific Medical Advisor relationship with American Lung Association; current; Scientific Medical Advisor relationship with Department of Defense; 2021; Advisory Committee Member relationship with Astra Zeneca; current; Consultant relationship with Wolters Kluwer Health (Up-To-Date); current; Advisory Committee Member relationship with Regeneron; 2023; Consultant relationship with Psammia; 2023; Disease state education presentations relationship with GlaxoSmithKline; 2022
Maldonado, Fabien (MD, FCCP)	research funding relationship with Erbe; 2024-2025; research funding relationship with Pleural Dynamics; 2024-2025; Research funding relationship with Candel Therapeutics; 2021-2024; Research funding relationship with Gala Therapeutics; 2021-2024; PI of an investigator-initiated study relationship with Medtronic; >\$100000; PI on investigator-initiated relationship with Erbe; \$5001 - \$20000; Consulting relationship with Medtronic; \$5001 - \$20000; research funding relationship with Steris; 2022-2025
Malhotra, Atul (MD)	Consultant relationship with powell mansfield; ongoing; Consultant relationship with zoll; ongoing; Consultant relationship with eli lilly; ongoing; Consultant relationship with livanova; ongoing
MAMMARAPPALLIL, JOE (MD, PhD)	Consultant relationship with BD Peripherals; Current; Consultant relationship with Boeringher Ingelheim; Current; Consultant relationship with Galvanize Therapeutics; Current
Mansour, Wissam (MD)	PI for industry sponsored trial grant relationship with Asklepios BioPharmaceutical, Inc; 07/01/2023

Marciniuk, Darcy (MD, Master FCCP)	Research relationship with Novartis - funds held and managed by University of Saskatchewan; Ongoing; Research relationship with Canadian Institute of Health Research; Ongoing; Research relationship with GlaxoSmithKline - funds held and managed by University of Sa; Ongoing; Research relationship with Grifols - funds held and managed by University of Saskatchewan; Ongoing; Research relationship with Lung Association of Saskatchewan; Ongoing; Employee relationship with University of Saskatchewan; Ongoing; Deputy Editor - Outreach relationship with CHEST; Ongoing; Research relationship with Saskatchewan Health Research Foundation; Ongoing; Research relationship with Schering-Plough - funds held and managed by University of Saskatchewan; Ongoing; Research relationship with Sanofi - funds held and managed by University of Saskatchewan; Ongoing; Scientific Medical Advisor relationship with Lung Association of Saskatchewan; Ongoing; Scientific Medical Advisor relationship with Saskatchewan Ministry of Health; Ongoing; Scientific Medical Advisor relationship with Saskatchewan Health Authority; Ongoing; Scientific Medical Advisor relationship with Yukon Health and Social Services; to 2021; Research relationship with Astra Zeneca - funds held and managed by University of Sask.; Ongoing; Research relationship with Boehringer Ingelheim - funds held and managed by University; Ongoing; Scientific Medical Advisor relationship with Health Canada; Ongoing
Marmor, Meghan (MD)	Speaker/Speaker's Bureau relationship with Insmed; 12/2024; Advisory Committee Member relationship with Flexpa; Feb 2020
Maselli, Diego (MD, FCCP)	Consultant relationship with Amgen; 10/1/2021; Consultant relationship with Sanofi/Regeneron; \$5001 - \$20000; Consultant relationship with GSK; \$5001 - \$20000; Consultant relationship with AstraZeneca; \$5001 - \$20000
Mathai, Stephen (MHS, MD, FCCP)	Advisory Board relationship with Merck; ongoing; Advisory Committee Member relationship with Janssen; past; Consultant relationship with Acceleron; past; Consultant relationship with GSK; ongoing; Consultant relationship with United Therapeutics; ongoing; Royalty relationship with Up To Date; ongoing
Matthay, Michael (MD)	Consultant relationship with Healios Pharmaceuticals; 2025; Research relationship with Quantum Therapeutics; 2020-2025; Consultant relationship with Merck Pharmaceuticals; 2024; Consultant relationship with CSL Behring; 2023; Research relationship with Roche-Genentech; 2019-2025
Matusov, Yuri (MD)	Site PI relationship with Penumbra; 10/2023-now; Investigator-Initiated Grant Recipient relationship with Mallickrodt; 10/2023-now; Site PI relationship with Aerovate Therapeutics; 01/2022-06/2024; Site PI relationship with BioAegis; 06/2025-present; Site PI relationship with Tenax; 06/2025-present; Scientific Medical Advisor relationship with Jupiter Endovascular; 07/2024-now

Maves, Ryan (MD, FCCP)	Consultant relationship with GSK; 8/01/2024-11/20/2024; Clinical trial support relationship with GeoVax; 1/1/2024-present; Clinical trial support relationship with Biotest; 1/1/2024-present; Clinical trial support relationship with AiCuris; 1/1/2022-present; Consultant relationship with GSK; 4/1/2024-7/31/2024; Advisory Committee Member relationship with Shionogi; 1/1/23-1/1/24; Clinical trial support relationship with Merck; 12/1/2024-present; Clinical trial support relationship with GeoVax; 11/01/2023 - present; Clinical trial investigator relationship with AiCuris; 11/15/2022-present; Advisory Committee Member relationship with Shionogi; 1/22/2023-present; Clinical trial support relationship with Eagle Pharmaceuticals; 11/01/2023 - present; Clinical trial investigator relationship with Sound Pharmaceuticals; 10/1/2021-05/2024
Mazzone, Peter (MPH, MD, FCCP)	Research support to my institution relationship with DELFI; 6/2021 - ongoing; Research support to my institution relationship with Veracyte; \$5001 - \$20000; Research support to my institution relationship with Nucleix; 6/2021 - ongoing; Research support to my institution relationship with Biodesix; 2021 -; Research support to my institution relationship with Adela; 2022 -
McCarthy, Cormac (MBBCh)	Advisory Committee Member relationship with Savara Inc.; 2023-Present
McLaughlin, Vallerie (MD)	Consultant relationship with Regeneron; current; Consultant relationship with Riovant; current; Scientific Medical Advisor relationship with Liquidia; current; Consultant relationship with Keros; current; Scientific Medical Advisor relationship with Keros; current; Consultant relationship with United Therapeutics; current; Consultant relationship with Merck; current; Consultant relationship with Janssen; current; Consultant relationship with Gossamer-Bio; current; Consultant relationship with Corvista; current; Consultant relationship with CVS/Caremark; current; Scientific Medical Advisor relationship with Merck/Aceleron; current; Scientific Medical Advisor relationship with Janssen; current; Scientific Medical Advisor relationship with Gossamer-Bio; current; Consultant relationship with Inhibikase; current; Consultant relationship with Liquidia; current; Consultant relationship with Morphic; current; Consultant relationship with Novartis; current; Consultant relationship with Respira; current
Mehta, Vishisht (MBBS, FCCP)	Research relationship with 4D Medical; one time - MAY 2025; Travel support relationship with Penumbra; one meeting APR 2023; Passive investor relationship with Oatmeal health; 10/2023 - current; Consultant relationship with Intuitive surgical; one meeting MAY 2023; ad-hoc/PRN clinical advisor relationship with Qure.ai; APR 2023 - OCT 2023; Advisory Committee Member relationship with Sanofi; one meeting OCT 2023; Consultant relationship with biodesix; OCT 2023 - current; trave relationship with Noah Medical; one visit JULY 2023

Melendres-Groves, Lana (MD)	Consultant relationship with Bayer Pharmaceuticals; \$1001 - \$5000; Advisory Committee Member relationship with United Therapeutics; \$5001 - \$20000; Speaker/Speaker's Bureau relationship with United Therapeutics; \$5001 - \$20000; Speaker/Speaker's Bureau relationship with Bayer Pharmaceuticals; \$5001 - \$20000; Consultant relationship with United Therapeutics; \$5001 - \$20000; Consultant relationship with Jansen Pharmaceuticals; 2019-Present; Speaker/Speaker's Bureau relationship with Jansen Pharmaceuticals; 2019-present; Consultant relationship with Merck Pharmaceuticals; 1/2022-current; Advisory Committee Member relationship with Merck Pharmaceuticals; January 2023-current; Speaker/Speaker's Bureau relationship with Liquidia Corporation; 6/2025-current
Menon, Aravind (MD)	Consultant relationship with Kinevant Sciences; 2023
Metersky, Mark (MD, FCCP)	DSMB member relationship with Verona; February 1, 2025-ongoing; Advisory Committee Member relationship with Boehringer-Ingelheim; 2022; DSMB member relationship with AN2; 6/30/23 to present; Advisory Committee Member relationship with Insmad; 2021-ongoing; DSMB member relationship with Renovion; 3/30/23 to present; Consultant relationship with Tactile Inc; 2022 to 3/30/23
Mielniczuk, Lisa	Consultant relationship with Merck; 2024; Consultant relationship with GSK; 2024
Miller, Andrew	n/a relationship with MedEx Research; 1/24-1/24; n/a relationship with Aerogen; 11/23-11/23
Mina, Bushra (FCCM, MD, FCCP)	Consultant relationship with Inari Medical; 2023
Minami, Taro (MD, FCCP)	Consultant relationship with FUJIFILM, project funded by the Ministry of Economy, Trade, and Industry (METI), Japan; Until March 2023; Consultant relationship with AA Health Dynamics, project funded by the Ministry of Economy, Trade, and Industry (METI), Japan; until January 2024; Consultant relationship with FUJIFILM, project funded by the Japan International Cooperation Agency (JICA); Until March 2022
Mireles-Cabodevila, Eduardo (MD)	Consultant relationship with IngMar medical; 2021 to present; Royalties relationship with Jones & Bartlett Learning; 2011-present; Editor book relationship with Elsevier publishers; 1/2023
Mittal, Aarti (DO)	Speaker/Speaker's Bureau relationship with Inari; 03/25- present
Mohan, Arjun (MBBS, MD)	Consultant relationship with Verona Pharma; 1 day; Consultant relationship with Regeneron Pharma; 1 day
Molyneaux, Phil (MD, PhD)	Advisory Committee Member relationship with TREVI; 2023-25
Morris, Timothy (MD, FCCP)	Research support relationship with Inari Medical; 2023-2025
Mullin, Monica (MD)	Research collaborator relationship with Grail LLC; May 2024
Munoz Pineda, Jorge (MD)	Researcher relationship with Ruby Robotics; July 2024 - July 2025; Consultant relationship with Intuitive; 03/2025 to present

Murgu, Septimiu (MD, FCCP)	Educational consultant relationship with Olympus, Pinnacle Biologics; ongoing
Mustafa, S Shahzad (MD)	Speaker/Speaker's Bureau relationship with Genentech; Ongoing; Speaker/Speaker's Bureau relationship with Regeneron/Sanofi; Ongoing; Speaker/Speaker's Bureau relationship with GSK; Ongoing; Speaker/Speaker's Bureau relationship with AstraZeneca; Ongoing; Speaker/Speaker's Bureau relationship with CSL Behring; Ongoing
Muthappan, Palaniappan (MD)	Speaker/Speaker's Bureau relationship with Edwards Lifesciences; 2025
Mylvaganam, Ruben	Advisory Committee Member relationship with United Therapeutics; 2023; Advisory Committee Member relationship with Roivant Sciences; 2023; Advisory Committee Member relationship with Janssen Pharmaceuticals; 2024
Naik, Sreelatha (MD, FCCP)	Advisory board relationship with AstraZeneca; 2024
Nair, Parameswaran	study grant relationship with Roche; 2023-2025; lecture fee relationship with GSK; 2022-2024; Advisory Committee Member relationship with Sanofi; 2021-2024; Advisory Committee Member relationship with AstraZeneca; 2022-2024; study grant relationship with Teva; 2021-2023
Nathan, Steven (MD, MBBCh, FCCP)	Consultant relationship with United Therapeutics; \$5001 - \$20000; Author relationship with Boehringer Ingelheim; 24 months; Consultant relationship with PureTech; January 2024; Advisory Committee Member relationship with AbbVie, Inc.; January 2025; Advisory Committee Member relationship with Bristol Myers Squibb; January 2025; Consultant relationship with AllRock; April 2025; Consultant relationship with Daewoong; January 2022; Consultant relationship with Avalyn; June 2023; Board Member relationship with Gossamer Bio; March 2024-; Speaker/Speaker's Bureau relationship with Boehringer-Ingelheim; \$20001 - \$100000
Newton, Chad (MD)	Consultant relationship with Boehringer-Ingelheim; 2/11/2021-2/10/2022, 2/1/2025-current
Neyra, Javier (MS, MD)	Consultant relationship with Baxter; 2023
Nobari, Matthew (MD)	Speaker/Speaker's Bureau relationship with Verona; October 2024; Consultant relationship with Merck; October 2023; Consultant relationship with Intuitive Surgical; 2024
Nunes, Hilario	Scientific Medical Advisor relationship with Boehringer Ingelheim; since 2023; Investigator of clinical trial relationship with Roche; 01/2023 to 01/2025; Investigator of clinical trial relationship with ATYR; 01/2023 to 01/2025; Investigator of clinical trial relationship with Pliant Therapeutics; 01/2023 to 01/2025; Investigator of clinical trial relationship with KINEVANT; 01/2023 to 01/2025; Investigator of clinical trial relationship with Bristol Myers Squibb; 01/2023 to 01/2025

O'Donnell, Anne (MD, FCCP)	grant to GU relationship with Insmed; 2020-present; Scientific Medical Advisor relationship with Zambon; 2020-present; grant to GU relationship with Paratek; 2020-present; grant to GU relationship with RedHill; 2020-present; grant to GU relationship with Boehringer Ingelheim; 2020 present; grant to GU relationship with Astra-Zeneca; 2020-present; grant to GU relationship with Zambon; 2020-present; Scientific Medical Advisor relationship with Boehringer Ingelheil; 2021-present; Scientific Medical Advisor relationship with Insmed; 2020-present; grant to GU relationship with AN2; present; grant to GU relationship with Armata; 2022; grant to GU relationship with Renovion; 2022- present; grant to GU relationship with Verona; 2024-ongoing; grant to GU relationship with Mannkind; 2024-ongoing
Oberg, Catherine (MD)	Faculty for fellows' education project relationship with Medtronic; July 2020 - June 2024; Consultant relationship with Intuitive; Current; Consultant relationship with Noah Medical; September 2022; Consultant relationship with Cook Medical; Current; Consultant relationship with Olympus; Current
Olivier, Kenneth (MPH, MD, FCCP)	Site Investigator relationship with AN2 Therapeutics; 2022 - current; Grant recipient relationship with Beyond Air; 2017-10/2023; Advisory Committee Member relationship with AN2 Therapeutics; 2022 - 2023; Investigator relationship with ReCode Therapeutics; 2022 - current; DSMB Chair relationship with Mannkind Corporation; 7/22/2024; Advisory Committee Member relationship with Spero Therapeutics; 2023 - current; Site Investigator relationship with Spero Therapeutics; 2023 - current; Site Investigator relationship with Paratek Pharma; 20243- current; Consultant relationship with Paratek Pharma; 2024 - current; Speaker/Speaker's Bureau relationship with Insmed, Inc; 2023
Orr, Jeremy (MD)	Advisory Committee Member relationship with Resmed; 4/19/2021-present; Advisory Committee Member relationship with Stimdia; 2023 - present

Panettieri, Reynold (MD)	Advisory Committee Member relationship with Praesidia Biotherapies Inc.; 12 months; Advisory Committee Member relationship with AstraZeneca; 24 months; Principal Investigator relationship with Medimmune; 24 months; Principal Investigator relationship with RIFM; 24 months; Advisory Committee Member relationship with Genentech; 24 months; Principal Investigator relationship with AstraZeneca; 24 months; Speaker/Speaker's Bureau relationship with AstraZeneca; 24 months; Principal Investigator relationship with ACTIV-1; 24 months; Speaker/Speaker's Bureau relationship with Sanofi/Regeneron; 12 months; Speaker/Speaker's Bureau relationship with Merck & Co.; 24 months; Consultant relationship with RIFM; 24 months; Advisory Committee Member relationship with RIFM; 24 months; Principal Investigator relationship with Genentech; 24 months; Speaker/Speaker's Bureau relationship with Merck & Co; 24 months; Speaker/Speaker's Bureau relationship with Sanofi; 24 months; Consultant relationship with AstraZeneca; 24 months
Patel, Sanjay (MD, FCCP)	Consultant relationship with Apnimed; 2022 -; Scientific Medical Advisor relationship with Mineralys; 2025 -; Grant recipient relationship with Philips Respironics; 2018-2022; Consultant relationship with SleepRes; 2025 -
Penz, Erika (MD)	Speaker/Speaker's Bureau relationship with AstraZeneca; > 3 years; Consultant relationship with AstraZeneca; > 3 years; Board Member relationship with CHEST Journal Associate Editor; > 1 year; Advisory Committee Member relationship with AstraZeneca; > 3 years; Advisory Committee Member relationship with GlaxoSmithKline; > 1 year; Speaker/Speaker's Bureau relationship with GSK; > 3 years; Consultant relationship with Roche; 1 year; Consultant relationship with Sanofi; > 2 years; Consultant relationship with GlaxoSmithKline; > 3 years; Clinical Trial research - To Institution relationship with AstraZeneca; > 2 years; Speaker/Speaker's Bureau relationship with Sanofi; > 2 years; Speaker/Speaker's Bureau relationship with Valeo; > 2 years; Speaker/Speaker's Bureau relationship with COVIS Pharma; > 2 years
Peters, Anju (MD)	Advisory Committee Member relationship with Merck; present; Advisory Committee Member relationship with Sanofi Regeneron; present; Advisory Committee Member relationship with AstraZeneca; present; Consultant relationship with GSK; Present; Research relationship with Sanofi Regeneron; Present; Institution relationship with AstraZeneca; 2020-2021; Consultant relationship with Chiesi; 2023; Consultant relationship with Eli Lilly; 2023-2024

Piazza, Gregory (MD)	Advisory Committee Member relationship with Thrombolex; 1/1/2019-current; Advisory Committee Member relationship with Penumbra; 1/2022-; research relationship with BMS/Pfizer; \$5001 - \$20000; research relationship with Alexion; \$5001 - \$20000; research relationship with BSC; \$5001 - \$20000; research relationship with Janssen; \$5001 - \$20000; research relationship with Esperion; ongoing; research relationship with Amgen; ongoing
Possick, Jennifer (MD)	Advisory Committee Member relationship with Bristol Myers Squibb; 2023-2024; Consultant relationship with Sophia Genetics; 2023-2025; Advisory Committee Member relationship with Eisai; 2023-2024; Consultant relationship with Day One Biopharmaceuticals; 2025 to present
Prero, Moshe (MD)	Consultant relationship with Roche; October 2023 -
Press, Valerie (MD)	Peer reviewer relationship with UpToDate; 06/01/2025 - present; Consultant relationship with Humana; 12/01/19-06/25/25
Preston, Ioana (MD)	Advisory Committee Member relationship with Liquidia; 2019-2025; DMC chair relationship with Tectonic; 2024-2025; Consultant relationship with Gossamer; 2023-2025; Advisory Committee Member relationship with United Therapeutics; 2015-2025; Advisory Committee Member relationship with Respira; 2019-2025; Advisory Committee Member relationship with Keros; 2022-2025; Advisory Committee Member relationship with Insmed; 2021-2025; Advisory Committee Member relationship with Merck; 2019-2025; Advisory Committee Member relationship with Janssen; 2015-2025
Priebe, Rebecca (MSN, FCCP)	Consultant relationship with Pulmonx; 2021- Feb 2024
Rackley, Craig (MD, FCCP)	Consultant relationship with Roche; 2023; Advisory Committee Member relationship with SCOPE Medical; 2024; Consultant relationship with Inspira; 1/1/2022-present
Rali, Parth (MBBS, MD, FCCP)	Consultant relationship with thinksonos; 2023-Current; Consultant relationship with Penumbra; 5 months; Consultant relationship with AIDOC; 8/124-current; Speaker/Speaker's Bureau relationship with Janssen; 2021-Current; Consultant relationship with Inari Medical; 2021-current; Consultant relationship with Thrombolex; 2022-Current; Consultant relationship with VizAI; 2022-Current
Ramaniuk, Aliaksandr (DO)	Speaker/Speaker's Bureau relationship with GSK; 06/2025
Rickman, Otis (DO, FCCP)	Consultant relationship with Medtronic/Covidien; 2009 - present; Consultant relationship with Noah Medical; 2021 - present; Consultant relationship with Intuitive; 1/21 - present
Risbano, Michael (MD, FCCP)	Advisory Committee Member relationship with Gilead; 2022; Advisory Committee Member relationship with Liquidia; 2024; Grant Support relationship with Shadyside Hospital Foundation; 2022-Current; Author relationship with Springer; 2022-present; Grant Support relationship with NHLBI; 2024-2029; Advisory Committee Member relationship with Merck; 2024

Rischard, Franz	research/grant relationship with Aerovate; 1/1/23; research support/grants relationship with Merck; 1/1/23; research/grant support relationship with Janssen; 1/1/23; research/grant relationship with Bayer; 1/1/23; research support/grants relationship with United Therapeutics; 1/1/23
Rivera-Lebron, Belinda (MD, MSCE, FCCP)	Grant relationship with Johnson & Johnson; 2021
Rochester, Carolyn (MD, FCCP)	COPD Advisory Board relationship with Boehringer Ingelheim; January 2023
Rogers, Linda (MD, FCCP)	Editorial Board Member relationship with Elsevier; 2022-2024; Scientific Medical Advisor relationship with Contrafact; 2023; Scientific Medical Advisor relationship with Sanofi US; 2019-present; Speaker/Speaker's Bureau relationship with Regeneron; 2024; Speaker relationship with Astra Zeneca; 2019-present; Research funding relationship with Sanofi Global; 2019-present; Scientific Medical Advisor relationship with Teva; 2022
Ross, Patrick (MD, FCCP)	Consultant relationship with Intuitive; 2010 current
Sachdeva, Ashutosh (MBA, MBBS, FCCP)	Consultant relationship with Intuitive Inc; Intermittent; Consultant relationship with MERit; 2 years; Scientific Medical Advisor relationship with AMBU; 1 year
Sadoughi, Ali (MD)	Stock option relationship with Leadoptik; 2023; Consultant relationship with Olympus; 2018; Stock Option, Consultant relationship with Alpha Tau Medical; 2019; Consultant relationship with Merit; 2023
Safdar, Zeenat (MD, MSc, FCCP)	Advisory Committee Member relationship with Bayer Pharmaceuticls; 2022-2024; Speaker/Speaker's Bureau relationship with Merck pharmaceutical; 2022-2024; Advisory Committee Member relationship with United therapeutics; \$5001 - \$10000; Consultant and speakers bureau relationship with Actelion pharmaceutical- J & J; \$5001 - \$10000; Consultant and speakers bureau relationship with Genetech; \$5001 - \$10000; speakers bureau and consultant relationship with Bohreinger ingelheim; \$5001 - \$10000
Samant, Maanasi	Advisory Committee Member relationship with Bayer Pharmaceuticals; 8/2023; Advisory Committee Member relationship with United Therapeutics; 7/2023
Sarmiento, Kathleen (MD, MPH)	PI on IIR relationship with ResMed; Study closed 10/2024
Satia, Imran (MD, MBChB)	Scientific Advisor Board relationship with Sanofi-Renegeron; 24 months; Principle Investigator relationship with GSK/Bellus; 18 months; Scientific Advisor Board relationship with Trevi Therapeutics; 18 months

Scholand, Mary Beth (MD, FCCP)	Advisory Committee Member relationship with genentech; 2020-2022; Advisory Committee Member relationship with Bristol Meyers Squibb; 2023 - present; Advisory Committee Member relationship with Abbie; 2025 to present; Advisory Committee Member relationship with PureTech; 2024 - present; Advisory Committee Member relationship with avalyn; 2024-present; Advisory Committee Member relationship with veracyte; 2020-2022; Speaker/Speaker's Bureau relationship with Boehringer Ingelheim; 2020-present; Advisory Committee Member relationship with united therapeutics; 2020-present
Schwalk, Audra (MBA, MD, FCCP)	Advisory Committee Member relationship with Ambu; 3/2023-3/2024; consultant relationship with Ambu; 3/2023-3/2024
Sciurba, Frank (MD, FCCP)	Grant Support relationship with Nuvaira, Inc; 5/2018-Present; Grant Support relationship with AstraZeneca; 2/2020-Present; Grant Support relationship with Verona Pharma; 4/2019-Present; Grant Support relationship with Pulmonx; 9/2014-Present; Grant Support relationship with Gala Therapeutics, Inc; 9/2018-Present; Grant Support relationship with Regeneron/Sanofi US Services, Inc; 5/2018-Present; Grant Support relationship with ResMed Corp; 8/2018-Present; Grant Support relationship with PneumRx; 10/2013-Present; Grant Support relationship with Gala Therapeutics, Inc; 9/2019-Present; Grant Support relationship with American Lung Association; 7/2021-Present; Grant Support relationship with PCORI; 6/2019-Present; Advisory Committee Member relationship with Glaxosmithkline (GSK); 2/2023; Grant Support relationship with PneumRx; 10/2012
Serra, Alexis	sub-investigator on a clinical trial relationship with CalciMedica, Inc.; 2025-present; sub-investigator for clinical trial relationship with Sedana Medical; 2022-2024
Sethi, Sanjay (MD)	Research funds to institution relationship with Regeneron; ongoing; Speaker/Speaker's Bureau relationship with Astra Zeneca; ongoing; Scientific Medical Advisor relationship with Astra Zeneca; ongoing; Clinical Event adjudication committee relationship with Pulmonx; ongoing; Speaker/Speaker's Bureau relationship with Glaxo Smith Kline; ongoing; Advisory Committee Member relationship with Boehringer Ingelheim; ongoing; Advisory Committee Member relationship with chiesi; ongoing; Advisory Committee Member relationship with sanofi/regeneron; 2023-2024; Research grant to institution relationship with chiesi; ongoing; Scientific Medical Advisor relationship with Nuvaira; ongoing; Speaker/Speaker's Bureau relationship with Boehringer Ingelheim; ongoing; Advisory Committee Member relationship with Glaxo Smith Kline; ongoing; Research grant to institution relationship with astra zeneca; ongoing

Shamsid-Deen, Nafis (MD, FCCP)	Advisory Committee Member relationship with Johnson & Johnson; 1/1/22-Present; Speaker/Speaker's Bureau relationship with Merck; 11/4/24-Present; Advisory Committee Member relationship with United Therapeutics; 1/1/2022-Present
Sharma, Anuja (MBBS, FCCP)	Other relationship with Intuitive; 2022-2024
Sheshadri, Ajay (MD)	Consultant relationship with Seagen Therapeutics; 11/1/23-Ongoing; Consultant relationship with ADC Therapeutics; 7/1/23-11/1/23; Advisory Committee Member relationship with Tract Biopharma; May 2025; Consultant relationship with Enanta Pharmaceuticals; 01/01/21-ongoing
Shlobin, Oksana (MD, FCCP)	Speaker/Speaker's Bureau relationship with United Therapeutics; 2020-2024; Consultant relationship with Merck; 2022-2024; Speaker/Speaker's Bureau relationship with Bayer; 2020-2022; Speaker/Speaker's Bureau relationship with Janssen&Janssen; 2020-2023; Consultant relationship with Aerami; 2022-2024; Consultant relationship with United Therapeutics; 2020-2024; Consultant relationship with Altavant; 2020-2022; Consultant relationship with Acceleron; 2020-2022
Silvestri, Gerard (MS, MD, Master FCCP)	Consultant relationship with biodesix; 20001-100000; Scientific Medical Advisor relationship with auris medical; \$20001 - \$100000; Consultant relationship with auris medical; 1001-5000; Consultant relationship with aztrazeneca; \$1001 - \$5000; Scientific Medical Advisor relationship with freenome; 1000-5000; research grant relationship with Qure ai; 1/1/23; Scientific Medical Advisor relationship with biodesix; \$20001 - \$100000; Scientific Medical Advisor relationship with olympus america; 5000-20000; Consultant relationship with olympus america; \$1001 - \$5000
Sitbon, Olivier (PhD, MD)	Consultant relationship with GSK; Past; Consultant relationship with Ferrer; current; Consultant relationship with Acceleron; past; Consultant relationship with MSD; current; Consultant relationship with Janssen; current; Consultant relationship with Gossamer Bio; Current; Consultant relationship with Altavant Sciences; Past; Consultant relationship with Respira Therapeutics; Current; Consultant relationship with Pulmovant; 2024; Consultant relationship with United Therapeutics; 2024; Consultant relationship with Liquidia; Current
Slovarp, Laurie (PhD)	Shareholder in the form of stock options relationship with Hyfe, Inc.; 1/1/24 to current
Sood, Namita (MBBS, FCCM, FCCP)	Consultant relationship with Merck; may 2023; Speaker/Speaker's Bureau relationship with bayer; Current; Speaker/Speaker's Bureau relationship with Boeinger Ingelheim; Current; Consultant relationship with united Therapeutics; April 2023
Spangenthal, Selwyn (MBChB)	One-off Ad Board relationship with Reckitt Benckiser; \$1001 - \$5000

Steiling, Katrina (MD, MSc)	Consultant relationship with CRICO; 5/2021-present; Grant relationship with Merck Foundation; 2024-present; Author relationship with NEJM Group; 4/2023-9/2023; Co-inventor on patents related to COPD relationship with Boston University; 6/2017 to present; Co-author on chapter on Gene Expression relationship with UpToDate; 2010-present; Grant relationship with American Cancer Society; 2024; Grant relationship with Genentech; 1/2025-present
Strek, Mary (MD)	Pulmonary Adjudication Committee member relationship with Pliant; April 2024-present; Consultant relationship with Boehringer Ingelheim; 2023-present; Advisory Committee Member relationship with Bristol Myers Squibb; 2023-present; Endpoint Adjudication Committee Member relationship with Fibrogen; 2020-2023; PI relationship with Boehringer-Ingelheim; 2017-present
Stringer, William (MD, FCCP)	Research Site relationship with NIH - Recover; 2023 - Present; Research Site relationship with PureTech; 2022 - Present; Consultant relationship with PPD DSMB; 2022-Present; Speaker/Speaker's Bureau relationship with Vyaire; 2024; Research Site relationship with AstraZeneca; 2023- Present; Clinical Research Site relationship with Genentech; 2021-2024; Consultant relationship with Syneos DSMB; 2018 to Present; Author relationship with Wolters Kluwer; 2011 to Present; Consultant relationship with Capricor; 2020 - Present; Consultant relationship with Prolaio; 2025 - Present
Strollo, Patrick (MS, MD, FCCP)	Advisory Committee Member relationship with Apnimed; Aug 2023 to present; Research Grant relationship with ResMed; \$1001 - \$5000; Consultant relationship with Jazz Pharmaceuticals; \$1001 - \$5000; Research Support relationship with Itamar Medical; \$1001 - \$5000; Consultant relationship with Inspire Medical Systems; \$1001 - \$5000; Scientific Medical Advisor relationship with Belluscura; \$1-\$1000; Scientific Medical Advisor relationship with Biologix; \$1-\$1000; Research Support relationship with Philips; \$1001 - \$5000
Styrvoky, Kim (MD)	Travel relationship with Intuitive Surgical, Inc; 10/2022-6/2023
Subramanian, Ram (MD, FCCP)	Consultant relationship with eGenesis; 11/22- 11/25; Consultant relationship with Baxter; 8/24-8/26; Consultant relationship with Mallinckrodt; 1/23- 12/23
Sundar, Krishna (MBBS, MD, FCCP)	Advisory Committee Member relationship with GlaxoSmithKline; May 16, 2024; Advisory Committee Member relationship with Trevi Therapeutics; Oct 18, 2025
Swenson, Colin (MD)	Speaker/Speaker's Bureau relationship with Insmmed, Inc.; 2019 to present
Tamae Kakazu, Maximiliano (MD, FCCP)	Consultant relationship with InflaRx; 5/2024. All the honorariums have been donated to Corewell Health Foundation.; Advisory Committee Member relationship with Pfizer; 2/2023; Consultant relationship with InflaRx; 5/2024; Consultant relationship with Pfizer; 3/2023. All the honorariums have been donated to Corewell Health Foundation.

Tanner, Nichole (MS, MD, FCCP)	research support relationship with Biodesix; 2019-present; research support relationship with Nucleix; 2021-present; research support relationship with Delfi; 2021-present; research support relationship with PrognomiQ; 2021-present; research support relationship with Veracyte; 2022-present; research support relationship with Exact Sciences; 2021-present
Thiboutot, Jeffrey (MD)	Investigator Initiated Trial relationship with ERBE; 2/21/2021-present; Consultant relationship with PleuralDynamics; 07/1/2024-3/26/2025
Tino, Gregory (MD, FCCP)	Principal Investigator relationship with COPD Foundation - Bronchiectasis and NTM Research Registry; Ongoing
Tomashefski, Sarah (NP-C, MSN, FCCP)	Panel speaker/ ad board participant relationship with Sanofi; 1/2025-Present; Advisory Board Participant relationship with GSK; 12/2024
Tonelli, Adriano (MD)	Advisory Committee Member relationship with Janssen; last year; Advisory Committee Member relationship with Merck; Last year
Trivedi, Kovid (MBBS, FCCP)	Shareholder - Public relationship with Gilead; Long term; Advisory board attendee relationship with Sanofi/Regeneron; Thrice in the last 2 years.; Shareholder - Public relationship with Eli Lilly; Long term; Shareholder - Public relationship with Pfizer; Long term; Speaker/Speaker's Bureau relationship with AstraZeneca; Ongoing; Advisory Committee Member relationship with CHEST; 2 years; Shareholder - Public relationship with Medtronic; Long term; Shareholder - Public relationship with GE health sciences; Long term
Tyler, Matthew	Consultant relationship with The Conversation Project; 04/24 to 04/25; Owner/Founder relationship with How To Train Your Doctor, LLC; 10/24 - present; Consultant relationship with Soothing Scents; 09/24; Social Media Content Creator relationship with Meta; 03/23 - present
Uchel, Toribiong (MD, FCCP)	Consultant relationship with Intuitive Surgical, Inc.; Apr 2024 to Present
Veljanovski, Jovica (MD)	Site Investigator relationship with Fischer & Paykel; 11/30/23 and ongoing; Site Investigator relationship with Sanofi; 10/1/2020 to 6/1/24; Site Investigator relationship with Patient Centered Outcome Research Institute; 9/1/2020 to current
Villalobos, Nicholas (MD)	Consultant relationship with Fujifilm Sonosite; 2022 - 2024; Consultant relationship with Ultrasight; 2024; Consultant relationship with Viatris; 2024; Consultant relationship with Fujifilm Sonosite; 2022-2024; Consultant relationship with Fujifilm Sonosite; 2024; Consultant relationship with Theravance/Viatris; 2024
Volker, Ellen (MD, FCCP)	Consultant relationship with Medtronic; 9/2023-10/2023; Consultant relationship with Intuitive; 2020-current

Wagh, Ajay (MD, FCCP)	Consultant relationship with Cook Medical; 9/2024-current; Consultant relationship with Ambu; 8/2022-current; Consultant relationship with Noah Medical; 4/2021-current; Speaker/Speaker's Bureau relationship with Biodesix; 11/2021-current
Wahidi, Momen (MD, MBA, FCCP)	Consultant relationship with Intuitive; 2 years; Consultant relationship with BD; 2023-present; Consultant relationship with Medtronic, Inc.; 2024-present; Consultant relationship with Cook; 2020-Present; Consultant relationship with Biodesix; 2024-Present; Consultant relationship with Olympus; 2019-Present; Consultant relationship with Verathon; 2021-present
Wald, Joshua (MD)	Advisory Committee Member relationship with Hoffmann-La Roche; 2024-current; Speaker/Speaker's Bureau relationship with Hoffmann-La Roche; 2024-current; Speaker/Speaker's Bureau relationship with GSK; 2023-current; Advisory Committee Member relationship with GSK; 2023-current; Speaker/Speaker's Bureau relationship with AstraZeneca; 2023-current; Advisory Committee Member relationship with AstraZeneca; 2024-current; Speaker/Speaker's Bureau relationship with Sanofi; 2024-current; Advisory Committee Member relationship with Sanofi; 2024-current
wand, ori (MD)	Advisory Committee Member relationship with GSK; 2020-2024; Speaker/Speaker's Bureau relationship with Kamada; 2020-2024; lecture fees relationship with Sanofi; 2020-2024; Speaker/Speaker's Bureau relationship with BI; 2020-2024; Speaker/Speaker's Bureau relationship with AstraZeneca; 2020-2025
Wechsler, Michael (MD)	Consultant relationship with AstraZeneca, Amgen, Regeneron, Glaxosmithkline, Sanofi/Genzy; 3 YEARS; Advisory Committee Member relationship with UPSTREAM BIO; 3 YEARS; Consultant relationship with Sound Biologics, Tetherex Pharmaceuticals, Uniquity Bio, Ver; 3 YEARS; Consultant relationship with Rapt Therapeutics, recludix Pharma, Roche/Genentech, Sentien; 3 YEARS; Consultant relationship with Verona Pharma, Zurabio.; 3 YEARS; Consultant relationship with Kymera, Merck, MyBiometry, Pharming, Phylaxis, Pulmatrix, Ra; 3 YEARS; Consultant relationship with Eli Lilly, Equillium, , Incyte, Jasper Therapeutics, Kinaset; 3 YEARS; Consultant relationship with Avalo Therapeutics, Belenos Bio, Celldex, Connect Biopharma;; 3 YEARS; Consultant relationship with Allakos, , Areteia Therapeutics, Arrowhead Pharmaceutical;; 3 YEARS
Weiss, Tyler (AE-C, RRT-ACCS, RRT, PhD, FCCP)	Consultant relationship with National Board for Respiratory Care; 2021-present

West, Frances (MD, MS)	Advisory Committee Member relationship with Inari Medical; ongoing; Advisory Committee Member relationship with Penumbra Inc; 6/21/2021 - present; Consultant, Speaker relationship with Inari Medical; 11/21/2023; Board Member relationship with PERT Consortium; ongoing; Participant providing Evaluation Service relationship with Exo; ongoing
Woller, Scott (MD, FCCP)	Recipient of Grant Funding relationship with Janssen Pharmaceuticals; 7/1/23- 03/31/25; Recipient of grant funding for research relationship with Grifols; 8/1/25-present
Wunderink, Richard (MD, FCCP)	Scientific Medical Advisor relationship with Bioaegis; 2 years; Consultant relationship with Calcimedica; 1 year; Consultant relationship with Karius; June 2024; Advisory Committee Member relationship with Aurobac; Nov 2024; Scientific Medical Advisor relationship with Helixbind; 5 years; Consultant relationship with Merck; 2-3 years; Consultant relationship with Shionogi; 2 years; Consultant relationship with Microbiotix; 5 years; Clinical Evaluation Committee relationship with Pfizer; 3 years
Yang, Jenny (MD)	Speaker/Speaker's Bureau relationship with Merck; August 2024; Advisory Committee Member relationship with Janssen; June 2023
Yorgancioglu, Arzu	Advisory Committee Member relationship with GSK; 2020; Speaker/Speaker's Bureau relationship with Chiesi; 2021; Speaker/Speaker's Bureau relationship with Sandoz; 2020; Speaker/Speaker's Bureau relationship with Abdi Ibrahim; 2021; Advisory Committee Member relationship with DEVA; 2020; Advisory Committee Member relationship with Astra Zeneca; 2020; Speaker/Speaker's Bureau relationship with Novartis; 2020
Young, Corinne (MSN, NP-C, FCCP)	Speaker/Speaker's Bureau relationship with Grifols; 01/01/2024; Speaker/Speaker's Bureau relationship with AstraZeneca; 01/01/2024; Advisory board relationship with Regenerol/Sanofi; 01/01/2024
Zafar, Muhammad (MD, MSc)	Owner/Founder relationship with PEP Buddy, LLC; Feb 2022 to date
Zarama, Virginia (MD)	Speaker/Speaker's Bureau relationship with Mindray; 09/23
Zul Jiwani, Ali (MD)	Consultant relationship with Intuitive Surgical; Jan 2022 to present; Consultant relationship with Siemens Healthineers; Feb 2024 to present